17-α estradiol ameliorates age-associated sarcopenia and improves late-life physical function in male mice but not in females or castrated males

Michael Garratt¹ | Danielle Leander¹ | Kaitlyn Pifer¹ | Brian Bower¹ |
Jonathan J. Herrera²,³ | Sharlene M. Day²,³ | Oliver Fiehn⁴ | Susan V. Brooks²,⁵ |
Richard A. Miller¹,⁶

Abstract
Pharmacological treatments can extend mouse lifespan, but lifespan effects often differ between sexes. 17-α estradiol (17aE2), a less feminizing structural isomer of 17-β estradiol, produces lifespan extension only in male mice, suggesting a sexually dimorphic mechanism of lifespan regulation. We tested whether these anti-aging effects extend to anatomical and functional aging—important in late-life health—and whether gonadally derived hormones control aging responses to 17aE2 in either sex. While 17aE2 started at 4 months of age diminishes body weight in both sexes during adulthood, in late-life 17aE2-treated mice better maintain body weight. In 17aE2-treated male mice, the higher body weight is associated with heavier skeletal muscles and larger muscle fibers compared with untreated mice during aging, while treated females have heavier subcutaneous fat. Maintenance of skeletal muscle in male mice is associated with improved grip strength and rotarod capacity at 25 months, in addition to higher levels of most amino acids in quadriceps muscle. We further show that sex-specific responses to 17aE2—metabolomic, structural, and functional—are regulated by gonadal hormones in male mice. Castrated males have heavier quadriceps than intact males at 25 months, but do not respond to 17aE2, suggesting 17aE2 promotes an anti-aging skeletal muscle phenotype similar to castration. Finally, 17aE2 treatment benefits can be recapitulated in mice when treatment is started at 16 months, suggesting that 17aE2 may be able to improve aspects of late-life function even when started after middle age.

1 | INTRODUCTION
With an increased proportion of individuals living to older ages, a greater proportion of the human population suffers from frailty and impaired physical function. Demographic models predict that the number of people living to old ages in high-income countries will increase (Colby & Ortman, 2017; Robine & Cubaynes, 2017), which presents a potentially substantial burden for healthcare and economic systems. Interventions that can slow age-related physical...
decline and improve health later in life would help to ameliorate this burden, while improving the quality of life for elderly adults. Pharmacological treatments are increasingly being recognized as potential methods to slow functional declines during aging in humans (Longo et al., 2015), in addition to reducing the incidence of age-associated morbidities and neurological decline.

One area of pharmacological research that has already received attention in the context of aging is steroid treatments that seek to redress alterations in circulating sex hormone concentrations that occur during later life. Manipulation of testosterone and estrogens can improve aspects of physical function in the elderly (Horstman, Dillon, Urban, & Sheffield-Moore, 2012; Stanworth & Jones, 2008), but can also elevate risks of certain diseases, including cancers and cardiovascular disease (Basaria et al., 2010; Chen & Colditz, 2007), potentially because of their strong binding affinity to classical steroid receptors across the body. More recently, other steroids, with lower binding affinities to classical sex hormone receptors, have been suggested as alternative treatments to protect against aging, while lessening side-effects of diseases linked to sex steroid hormone signaling (Gonzalez-Freire, Díaz-Ruíz, & Cabo, 2016; Madak-Erdogan et al., 2016). 17-α estradiol (17αE2), a less feminizing structural isomer of 17-β estradiol, has been shown to extend lifespan in male mice (Strong et al., 2016), while also improving glucose tolerance and lowering the abundance of circulating inflammatory cytokines (Garratt, Bower, Garcia, & Miller, 2017; Stout et al., 2016). Effects of 17αE2 on lifespan and metabolism are strongly sex-specific, with neither lifespan (Strong et al., 2016) nor adult glucose tolerance (Garratt, Bower et al., 2017) detectably affected by 17αE2 in female mice.

While 17αE2 has male-specific benefits for survival, we have limited understanding of whether these effects extend to functional, pathological, or biochemical age-associated changes, and whether slowed aging responses outside of survival also differ between males and females. Furthermore, we currently have a poor understanding of what mechanisms underlie sexual dimorphism in response to anti-aging interventions, observed with 17αE2, but also an increasing number of other pharmacological and genetic interventions (Austad & Fischer, 2016), including reduced IGF1 (Garratt, Nakagawa & Simons, 2017; Holzenberger et al., 2003) and mTORC1 signaling (Garratt, Nakagawa, & Simons, 2016; Lamming et al., 2012; Selman et al., 2009). Our previous research has shown that sex-specific metabolic responses to 17αE2 in adulthood are linked to the presence of male gonads, such that male-specific improvements in glucose tolerance are inhibited if males are castrated prior to the onset of treatment (Garratt, Bower et al., 2017; Garratt et al., 2018). However, whether gonadal hormones control the anti-aging effects of 17αE2, or any other sexually dimorphic anti-aging manipulation, has not been tested.

In this study, we show that 17αE2 treatment has anti-aging effects for body weight regulation, muscle weight, and physical function, and that these effects differ strongly between males and females. We used two independent cohorts of mice to probe these effects, while establishing the underlying hormonal causes for the observed sex-specificity, and to test whether the anti-aging effects of this treatment can be recapitulated by treatment beginning in middle age. In cohort 1, all mice underwent a brief surgery at 3 months of age, where gonads (testes or ovaries) were either removed (gonadectomy) or exposed but remained in place (sham gonadectomy). These animals then began 17αE2 treatment at 4 months of age, or stayed on a control diet, and were euthanized at 25 months. Animals in cohort 2 did not undergo any surgery and were euthanized at 22 months. The main cohort of animals began 17αE2 treatment at 4 months, while a subset remained on the control diet until 16 months of age, but were then switched to 17αE2 treatment at 16 months of age. This allowed us to test whether a late onset treatment of 17αE2 can also produce functional benefits later in life, and to compare the anti-aging effects of treatment onset at these two time points.

# RESULTS

## 2.1 17αE2 maintains body weight during aging in both sexes, but has sex-specific effects on body composition: intact, sham-operated animals (Cohort 1)

In the first cohort of mice treated with 17αE2 from 4 months, we recorded body weight monthly across life (Figure 1a). Effects of 17αE2 on body weight differed depending on life-stage (p = 0.001 for the interaction between 17αE2 treatment and time in a repeated measures ANOVA of monthly body weights), but were similar in intact (sham-operated) animals of both sexes (p = 0.32 for the 3-way interaction between sex, treatment, and time; p = 0.61 for the interaction between sex and treatment; Figure 1b), as previously reported (Strong et al., 2016). 17αE2 reduces weight gain over approximately the first 12 months of life (Figure 1b), as shown by the change in weight between 4 and 9 months in Figure 1b. This presumably reflects the reduction in adiposity that occurs with the onset of 17αE2 treatment (Steyn et al., 2018; Stout et al., 2016). However, we observed that during aging, 17αE2 slows the decline in body weight that occurs over late-life periods. This is most clearly illustrated by the change in weight between 19 and 24 months of age (Figure 1b). At 25 months, all animals were euthanized, and major organs and fat pads weighed, allowing us to test whether late-life weight effects were linked to alterations in the weight of specific tissues (see Supporting Information Table S1 for weights of all tissues). In female mice, 17αE2 increased the weight of subcutaneous inguinal fat at 25 months (Figure 1c), apparently contributing to the maintenance of body weight between 19 and 24 months in females. In males, 17αE2 did not significantly alter the weight of inguinal fat (Figure 1c) but led to an increased skeletal muscle weight at 25 months as assessed by quadriceps weight (Figure 1d). This effect of 17αE2 persists whether assessing total muscle weight or muscle weight corrected by body weight (Figure 1d) and represents a significant sex-specific response, in that there was a significant interaction between sex and treatment in an ANCOVA model including body weight as a covariate (Table 1). The effect of 17αE2 on muscle weight...
FIGURE 1  Changes in body weight, skeletal muscle, and subcutaneous fat weight in male and female mice treated with 17aE2. Data presented in (a) show the mean body weights of male and female mice from cohort 1 on control or 17aE2 diets across life, while in (b), the change in weight is shown calculated from two specific time points. Data in (c) and (d) show the weights of inguinal fat and quadriceps at dissection, either plotted against body weight individually for each mouse, or the mean weight of each group. Error bars represent the standard error of the mean (SEM). p values for quadriceps and inguinal weight were calculated from a Student’s t test. N = 11–20 per group.
weight was also age-specific, since quadriceps weight in a subset of animals from cohort 1 euthanized at 12 months of age was not altered by 17aE2 treatment (Supporting Information Figure S1A), and muscle weight of 25-month-old control animals was significantly lower than in muscles taken from a set of 6-month-old untreated animals of the same strain that were euthanized, dissected, and weighed over the same period (Supporting Information Figure S1B).

### 2.2 | 17aE2 maintains skeletal muscle fiber size during aging in male mice: intact animals (Cohorts 1&2)

To understand whether the delay in sarcopenia represents changes at the level of the individual muscle fibers, we first measured muscle fiber size at 25 months. Fiber cross-sectional areas (CSA) were measured in gastrocnemius muscles collected from animals in cohort 1 and fixed in 10% buffered formalin immediately at dissection. Compared to samples taken from 6-month-old young controls, 25-month-old intact control mice showed a reduction in average muscle fiber CSA, an effect that was ameliorated in intact male mice treated with 17aE2 from 4 months (Figure 2a,b; Table 1). Fiber CSA showed a similar response to 17aE2 treatment in intact female mice (Figure 2b; Table 1). We also observed that intact male mice treated with 17aE2 maintained typical muscle fiber morphology during aging and did not present the severe angular deformation of muscle fibers observed in untreated old animals (Hepple, Ross, & Rempfer, 2004; Purves-Smith, Solbak, Rowan, & Hepple, 2012) (Figure 2c). This represents a sex-specific response as indicated by the sex by treatment interaction term (Table 1) and the lack of response in this parameter in 17aE2 treated females (Figure 2c). Old animals also showed characteristic accumulation of fibers with central nuclei, a change that was not significantly inhibited by 17aE2 treatment in either sex (Table 1; Figure 2d).

The gastrocnemius muscle is made up of a mix of muscle fiber types, although the large majority are type 2b fast-twitch muscle fibers. Fast-twitch muscle fibers typically show the greatest atrophy during aging, with fewer changes observed in slow-twitch oxidative fibers (Russ, Gregg-Cornell, Conaway, & Clark, 2012). In the second cohort of mice sampled at 22 months, we assessed whether the effects of 17aE2 on muscle fiber size were fiber type specific, by examining the size of individual muscle fibers of different fiber types within the gastrocnemius muscle. Given the increase in fiber size observed in the gastrocnemius muscles of cohort 1, we also weighed gastrocnemius muscles of animals in cohort 2, which showed that this skeletal muscle was significantly heavier in 17aE2-treated male mice compared to controls ($p = 0.006$, data are plotted in a

### Table 1 | Effect of age, 17aE2 treatment and sex on skeletal muscle and functional traits. $p$ values for age effects represent the main effect of age in a 2-way ANOVA, including both age and sex as variables. $p$ values for interaction terms were also calculated from a 2-way ANOVA, including an effect of treatment (control or treatment) and a second term representing either sex or surgical status. For quadriceps weight, body weight was also included as a continuous covariate in the analysis to account for variation in body weight across mice.

| Cohort | Effect of age | $p$ value | Effect of 17aE2 treatment interaction | Surgery by treatment interaction: Male | Surgery by treatment interaction: Female |
|--------|--------------|-----------|--------------------------------------|--------------------------------------|--------------------------------------|
| Quadriceps weight | Decreased | <0.001 | Increased in males | 0.004 | <0.001 | 0.34 |
| Gastrocnemius fiber size | Decreased | 0.006 | Increased ($p = 0.010$ for both sexes) | 0.91 | | |
| Angular atrophy of fibers | Increased | 0.001 | Decreased in males | 0.030 | 0.010 | 0.78 |
| Rotarod Performance | Decreased | 0.006 | Increased in males | 0.064 | 0.010 | 0.80 |
| Centralization of fiber nuclei | Increased | 0.006 | — | — | — | — |
| Gastrocnemius weight | Decreased | 0.058 | Increased in males | 0.041 | Not tested |
| Grip strength | Decreased | <0.001 | Increased in males | 0.047 | Not tested |
| Type 2b fiber CSA (gastro) | Decreased | 0.037 | Increased ($p = 0.018$ for both sexes) | 0.24 | | |
| Type 2a fiber CSA (gastro) | Unchanged | — | — | — | — | |
| Type 1 fiber CSA (gastro) | Unchanged | — | — | — | — | |
| Type 1 CSA (Soleus) | Unchanged | — | — | — | — | |
| Type 2a CSA (Soleus) | Unchanged | — | — | — | — | |
| Type 2a CSA (Soleus) | Unchanged | — | — | — | — | |

*GARRATT ET AL.*
**Figure 2** Increased skeletal muscle fiber size and reduced atrophy in 17αE2 treated male mice. (a) Representative images of cross-sections of gastrocnemius muscles (×20 magnification) from young (6 months), old (25 months), and old mice treated with 17αE2. (b) Average fiber CSA determined from cross-sections of the gastrocnemius muscle, while (c) and (d) show scores for degree of angular atrophy and centralization of nuclei across different treatment groups in cohort 1 (25 months). (e) Type-2b fiber CSA from mice in cohort 2 (sampled at 22 months). Error bars represent SEM. *p* values are calculated from a Student’s *t* test. *N*=8–15 per group for panels a–d, 5–6 for Figure 2e.
subsequent figure (Figure 6)), with no change in females, demonstrating a sex-specific response (Table 1). 17αE2 treatment increased the CSA of fast-twitch glycolytic type2b muscle fibers in gastrocnemius muscle (Figure 2e), without affecting the CSA of oxidative type 1 or type 2a fibers, which also did not change significantly with age (Table 1; Supporting Information Figure S2; see Supporting Information Figure S2 for representative images for each muscle fiber type). We also assessed CSA of muscle fibers in the soleus muscle, which is comprised almost entirely of type 1 and type 2a muscle fibers, with type 2b fibers absent (Kammoun, Cassar-Malek, Meunier, & Picard, 2014). Data from soleus muscles further demonstrated a lack of change in the size of these oxidative skeletal muscle fibers with aging (Supporting Information Figure S3)—consistent with previous reports (Williams, Higgins, & Lewek, 2002)—or 17αE2 treatment (Supporting Information Figure S3), indicating a predominant effect of 17αE2 on fast-twitch muscle fibers. In cohort 2, we also measured the weight of the quadriceps muscles. Similar to the findings in the 25-month-old mice of cohort 1, at 22 months the quadriceps muscle weight was greater in 17αE2 treated male mice than in untreated controls (Supporting Information Figure S1C), although at this age the p value did not reach the traditional criterion for statistical significance (p = 0.052).

2.3 | 17αE2 treatment improves grip strength and rotarod performance in aging intact male mice (Cohorts 1&2)

To test whether the effects of 17αE2 treatment on muscle aging are associated with improvements in late-life physical function, we assessed forepaw grip strength and rotarod performance. Forepaw grip strength was assessed at 22 months in cohort 2 and was lower in these animals than in a comparable set of 6-month-old controls (Figure 3a; Table 1). 17αE2 treatment improved male grip strength but had no effect on female grip strength (Figure 3a). We assessed rotarod performance at 24 months of age in cohort 1 using an acceleration protocol where mice were tested for their ability to balance on a progressively accelerating rotarod. The ability of mice to maintain balance on the rod declines with age, while 17αE2 treatment significantly improves balance ability in intact male mice (Figure 3b). Female performance was not affected by 17αE2 treatment, and these sex-specific effects were also replicated independently in cohort 2 (shown in subsequent Figure 6). We also tested whether differences in performance under these tests could be accounted for by changes in body weight that can occur with 17αE2 treatment. The relationship between grip strength and body weight across male

![FIGURE 3 17αE2 increases grip strength and rotarod capacity of aging male mice. (a) Forepaw grip strength in 22-month-old male and female mice treated with 17αE2, and young (6 months) and old (22 months) controls (cohort 2, N = 8–9 per group for males, 8–29 for females). (b) Rotarod capacity in 24-month-old male and female mice treated with 17αE2, young (6 months) and old controls (24 months) (n = 15–20 per group). (c) The relationship between grip strength/rotarod capacity and body weight in old male mice, with each dot representing values for an individual mouse. Error bars represent SEM and p values are calculated from a Student’s t test]
mice was not significant ($p = 0.79$ for effect of body weight as a covariate), suggesting that variation in body weight between groups does not account for the improved grip strength in male mice treated with 17aE2. Rotarod performance was negatively related to body weight (Figure 3c; $p = 0.002$ for effect of body weight as a covariate). When this negative relationship was accounted for by including weight as a covariate, mice treated with 17aE2 still showed improved rotarod performance relative to body weight (Figure 3c), although the $p$-value for an effect of 17aE2 treatment in cohort 1, when including body weight as a covariate, failed to reach statistical significance ($p = 0.062$). We note that the same relationship between body weight, rotarod performance, and 17aE2 treatment was observed in males in cohort 2 at 22 months. Combining both data-sets to increase statistical power revealed a significant effect of 17aE2 treatment in male mice across both cohorts ($p = 0.015$), even when accounting for variation in weight by including body weight as a covariate.

### 2.4 | 17aE2 generates sexually dimorphic responses in skeletal muscle amino acid abundance (Cohort 1)

To test whether sex-specific morphological responses to 17aE2 during aging were matched by sex-specific biochemical changes in muscle, we conducted an untargeted analysis of primary metabolites in quadriceps muscle sampled at 25 months from Cohort 1. Using a 2-way ANOVA to identify metabolites showing a sex-specific response to 17aE2 in intact (sham-operated) animals, we observed 8 metabolites that showed a significantly different response to 17aE2 treatment in each sex after correction for FDR, $p$ values presented in this table are uncorrected for multiple comparisons.

| Metabolite      | Treatment interaction ($p$-value 2-way ANOVA) | Effect of 17aE2 ($p$-Value Student’s t test) |
|-----------------|-----------------------------------------------|---------------------------------------------|
|                 | Sex (intact mice)  | Cast (male)  | OVX (female)  | Male | Female | Cast Male | OVX Female |
| Sample size control | 8 7 8 8 | Sample size 17aE2 | 9 8 8 8 |
| Sex-specific metabolites | | | | | | | |
| Isoleucine | 0.00003 | 0.015 | 0.15 | 0.011 | 0.001 |
| Serine | 0.00011 | 0.005 | 0.018 | 0.003 | 0.019 |
| Aspartic acid | 0.0005 | 0.003 | 0.002 | 0.019 | 0.009 | 0.087 | 0.066 |
| Leucine | 0.00075 | 0.52 | 0.029 | | | | |
| Valine | 0.001 | 0.020 | 0.039 | 0.056 | 0.005 |
| Glycolic acid | 0.00152 | | | | | | |
| Phenylalanine | 0.0027 | 0.010 | 0.031 | 0.028 | 0.044 |
| Methionine | 0.0027 | 0.001 | 0.039 | 0.006 | | 0.092 |
| Other amino acids | | | | | | | |
| Tryptophan | 0.030 | 0.008 | 0.17 | | | 0.073 |
| Threonine | 0.006 | 0.005 | 0.24 | | | 0.002 |
| Lysine | 0.021 | 0.001 | 0.15 | | | 0.015 | 0.042 |
| Glycine | 0.018 | 0.048 | 0.25 | | | 0.062 |
| Glutamic acid | 0.12 | 0.50 | 0.044 | | | 0.087 |
| Cysteine | 0.005 | 0.029 | 0.054 | | | 0.072 | 0.032 |
| Alanine | 0.86 | 0.48 | 0.76 | | | | 0.093 |
**FIGURE 4** 17αE2 causes a sex-specific amino acid response in quadriceps that is regulated by gonadal hormones. (a) Metabolites showing a sex-specific treatment response. Box plots tails show min and max values. (b) Principal component analysis showing amino acid factor loadings for PC1 and sex, treatment and surgery scores for PC1. (c) LC3BII and (d) 4EBP1 abundance in mice of different surgical, sex and treatment status, assessed in whole cell muscle homogenate using western blot. Error bars represent SEM and *p* values are calculated from a Student’s *t* test. *N* = 6–8 per group.
increasing amino acids and females showing a significant reduction (Figure 4b).

2.5 | Sex-specific amino acid responses to 17aE2 are dependent on gonadal hormones (Cohort 1)

We used the principal component analysis to test whether the sex-specific amino acid responses to 17aE2 were dependent on the production of gonadally derived hormones, by comparing metabolite responses to 17aE2 in mice that were gonadectomized at 3 months, prior to 17aE2 treatment, with responses observed in sham-operated (intact) animals. While intact males show an elevation in amino acids with 17aE2 treatment, this effect is blocked in males that were castrated prior to drug treatment. This is reflected in the lack of response in PC1 to 17aE2 treatment in castrated males (Figure 4b), and the failure of 17aE2 treatment to increase the abundance of any amino acid in castrated males (Table 2). In a 2-way ANOVA of PC1 scores comparing the effect of surgical status (intact or castrated) and drug treatment (control or 17aE2) in male mice, there is a strong interaction term (p = 0.003), further demonstrating that the male response to 17aE2 depends on the presence of male gonads. In females, ovariectomy prior to treatment also blocked the female-specific declines in amino acids (Figure 4b), and there was an interaction between surgical status and treatment (p = 0.011), indicating that the amino acid responses to 17aE2 in intact animals of both sexes were linked to the presence of male and female gonads.

Increased amino acids in muscle may represent a consequence of altered protein synthesis or breakdown, both of which can be regulated by the actions of gonadally derived hormones (Rossetti, Steiner, & Gordon, 2017). To explore whether sexually dimorphic responses to 17aE2 extend to mechanisms regulating protein synthesis and autophagy, we assessed the status of protein substrates involved in autophagy and protein translation in samples taken from a subset of animals in cohort 1 at 12 months of age. Males and females show a strong difference in relative LC3BII to LC3BI levels, a marker of autophagosome formation, with females having greater LC3BII relative to LC3BI, as previously reported (Tao et al., 2018). This could be a consequence of either greater autophagosome formation or slowed autophagic degradation in female mice (Mizushima & Yoshimori, 2007). Importantly, the sex difference is completely lost with 17aE2 treatment, with males and females showing different responses to 17aE2 treatment (sex by treatment interaction term: p = 0.002). Specifically, males show an increase in relative LC3BII abundance after 17aE2 treatment (Figure 4c), while LC3BII declines in 17aE2-treated females. In untreated animals, male castration increases LC3BII, as previously reported (Serra et al., 2013), and female ovariectomy reduces LC3II (Figure 4c). Neither castrated males nor ovariectomized females show a significant change in LC3II levels with 17aE2 treatment. The surgery by treatment interaction test within each sex provides statistical support for a different response to 17aE2 treatment in OVX females compared to intact females (p = 0.008), but not in the comparison with castrated to intact males (p = 0.18).

We also examined effects of 17aE2 on mTORC1 signaling, a key regulator of protein synthesis that has sexually dimorphic effects on physiology and aging in mice (Lamming et al., 2012). We observed no changes in relative phosphorylation of S6 and 4EBP1, downstream targets of mTORC1 (Supporting Information Figure S5). We also assessed total protein levels of 4EBP1, since genetically engineered over-expression of 4EBP1 can protect against male-specific adiposity and dysregulated insulin sensitivity (Tsai et al., 2015). Relative 4EBP1 protein levels are strongly reduced in male mice treated with 17aE2 (Figure 4d), but unaffected by treatment in females, with the sex difference in protein levels seen in animals on the control diet lost with 17aE2 treatment (sex by treatment interaction: p = 0.006). The sex difference in 4EBP1 protein levels is also not observed in gonadectomized animals on the control diet (Figure 4d), although these animals show a similar response to intact animals when treated with 17aE2 (surgery by treatment interaction p > 0.1 in both sexes).

2.6 | Functional and structural responses to 17aE2 are blocked by male castration (Cohort 1)

We also assessed whether sex-specific responses to 17aE2 in muscle structure and function were regulated by gonadal hormones, by comparing responses to 17aE2 in sham-operated and castrated animals in cohort 1. Males castrated prior to 17aE2 treatment showed no increases in the weight of the quadriceps muscle with 17aE2 treatment (Figure 5a: data for sham-operated males are replicated from Figures 1, 2), indicating that the male-specific response only occurs in males exposed to testicular production of hormones from 3 months of age. Castrated males have larger quadriceps muscle weights than intact males on the control diet at 25 months, and 17aE2 treatment in intact males causes an increase in quadriceps weight to the level seen in untreated castrated males. This effect was the opposite of the castration effect in untreated animals on muscle weight seen in a subset of animals dissected at 12 months of age, where castrated males tended to have a lighter quadriceps (Supporting Information Figure S6), consistent with the short-term effects of castration on skeletal muscle weight in adulthood (Jiao, Pruznak, Huber, Vary, & Lang, 2009). Similar to quadriceps weight, castrated male mice show no change in muscle fiber size with 17aE2 treatment, and again untreated castrated males have a larger skeletal muscle fiber CSA than that of equivalent untreated intact males (Figure 5b). This lack of responsiveness to 17aE2 treatment was also observed at the functional level, since castrated males showed no improvement in rotarod acceleration capacity with 17aE2 treatment (Figure 5c: intact male data are replicated from Figure 3). Intact and castrated males did not differ significantly in their rotarod scores in the untreated state. Females that were ovariectomized prior to treatment show similar treatment responses for each of these traits when compared to intact females (Table 1) and also showed an increase in
inguinal fat mass similar to that observed in intact females (Figure 5d; surgery (OVX versus intact) by treatment interaction: $p = 0.81$).

2.7 | Anti-sarcopenic benefits of 17aE2 can be recapitulated by late-life treatment (Cohort 2)

In the second cohort of animals exposed to 17aE2 treatment, we evaluated a randomly selected subset of mice where treatment with 17aE2 began at 16 months of age. This allowed us to test whether the benefits of 17aE2 treatment for skeletal muscle aging and physical function could be recapitulated with a treatment beginning after middle age, an approach that may have advantages in some clinical settings if applied to humans. Male mice treated with 17aE2 from 16 months showed a larger gastrocnemius muscle weight at 22 months when compared to untreated animals, with this improvement being equivalent to that seen in individuals treated from 4 months (Figure 6a). The line of best fit shown in Figure 6a overlaps in male mice treated from these two different age points, making it difficult to discern the two lines in the figure panel. Female mice treated with 17aE2 from 16 months do not show a change in gastrocnemius muscle weight when compared to controls or animals treated with 17aE2 from 4 months.

This cohort of animals was also assessed for accelerating rotarod balance capacity. Like cohort 1, intact male mice treated with 17aE2 again showed an improved rotarod capacity, with males treated from 16 months of age showing an equivalent improvement.
in performance to that seen with treatment from 4 months (Figure 6b). We further assessed the endurance capacity of mice by testing them at a lower and fixed rotation speed over a longer duration. Male mice treated with 17aE2 showed a longer endurance capacity than untreated males. The difference between control mice and mice treated with 17aE2 from 16 months was statistically significant, showing a benefit of late-life treatment, whereas the difference between mice treated from 4 months and controls did not reach statistical significance (Figure 6c).

3 | DISCUSSION

Pharmacological treatments that extend the lifespan of laboratory organisms deserve consideration as guides to interventions that could improve healthy aging in humans (Longo et al., 2015). A key criterion is that lifespan extension should be associated with improved physical function and health, which has not always been met when functional tests have been performed on long-lived animals (Bansal, Zhu, Yen, & Tissenbaum, 2015; Richardson et al., 2015). In this study, we show that the lifespan extension observed with 17aE2 is associated with reduced age-associated sarcopenia and improved late-life physical function, benefits that can be gained even from a 6-month treatment period beginning at middle age. However, these effects largely occur in a sex-specific manner, matching the lifespan response seen with this treatment (Strong et al., 2016). Among the outcomes we tested, only elevations in skeletal muscle fiber size and altered body weight occurred to a similar degree in both sexes. The similar changes in body weight with 17aE2 in both sexes are particularly notable, since reductions in body weight with the onset of 17aE2 treatment have been linked to reduced feeding behavior as a consequence of actions at hypothalamic pro-opiomelanocortin (POMC) expressing neurons (Steyn et al., 2018). The observation that body weight declines in both sexes with 17aE2, but functional benefits occur only in males, could suggest that the beneficial anti-aging effects of 17aE2 are not purely a consequence reduced body weight and consumption of fewer calories, because we would expect this to benefit both sexes. Ultimately, normalization of food intake between controls and 17aE2 is required to definitively test this, either via a controlled feeding approach or by using a mouse model without functional POMC expression. Previous use of mice lacking POMC expression has shown some metabolic responses to 17aE2 can occur without changes in weight and feeding (Steyn et al., 2018), supporting the hypothesis that health benefits of 17aE2 are independent of reductions in calorie intake.

We used an untargeted primary metabolism screen to identify metabolic responses that are linked to the observed male-specific
elevations in skeletal muscle weight during aging. This demonstrated that 17αE2-treated males show an increase in amino acids in quadriceps at 25 months. Notably female mice instead showed a decline in the abundance of some amino acids with 17αE2, although these females had muscle weights equivalent to control animals, indicating the relationship between 17αE2, muscle weight, and amino acid abundance is not bidirectional. In a previous study, we observed that this elevation in males (and decline in females) is not observed in quadriceps taken from animals with equivalent treatment sampled at 12 months of age (Garratt et al., 2018), indicating that effects of 17αE2 on the metabolome may differ depending on age, matching the age-specific effects on muscle weight. To directly test whether the observed elevations in amino acid levels occur as a consequence of net alterations in protein synthesis or breakdown requires metabolic flux analysis, which was not possible in the long-term aging studies designed here. However, our results suggest that 17αE2 induces changes in cellular processes involved in both protein synthesis and autophagy in adult mice, and these responses correspond to changes in amino acids in terms of reducing a sex difference observed in animals on a control diet. LC3BII levels were elevated in male mice treated with 17αE2, indicating altered autophagosome formation. In addition, total 4EBP1 abundance was reduced, without altered phosphorylation at sites activated by mTORC1. 4EBP1 is a translation initiation factor that when associated with eIF4E inhibits cap-dependent translation. A reduction in abundance of 4EBP1 is expected to promote protein translation (Morita et al., 2013). Given the role of both autophagy and protein translation in the causal control of the aging in some species (Hansen & Rubinsztein, 2018; Steffen & Dillin, 2016), detailed studies that directly assess the effects of 17αE2 on autophagic flux, protein synthesis, and metabolomic flux, in both sexes, may provide an insight into sexually dimorphic cellular processes that modulate muscle mass and turnover during aging.

Our study was designed to provide causal insight into the endocrine mechanisms that underlie sex-specific responses to 17αE2, and demonstrates that anti-aging responses to this treatment are controlled by the presence of sex-specific gonads. These results are consistent with our previous research showing that metabolic responses to 17αE2 in adult life are also dependent on gonadal hormones (Garratt, Bower et al., 2017; Garratt et al., 2018). We observed that skeletal muscle phenotypes induced by 17αE2 partly resemble those observed in untreated castrated males, and that castrated males do not respond to 17αE2 treatment, either in relation to muscle weight, physical function, or in their quadriceps metabolomic response. We have tested whether 17αE2 reduces circulating levels of testosterone in male mice but detected no observable decline in circulating testosterone levels in response to this treatment (Supporting Information Figure S7). However, testosterone is released from the testes in a pulsatile manner (Coquelin & Desjardins, 1982), making it difficult to accurately assess some measures of testosterone exposure without detailed kinetic studies. In a new cohort of C57BL/6J mice treated with 17αE2 from 3 months of age for seven weeks, we observed a highly consistent reduction in seminal vesicle weight (Supporting Information Figure S7), a reproductive organ that is very sensitive to circulating testosterone and its metabolite dihydrotestosterone (DHT), a more potent androgen in terms of binding affinity to the androgen receptor. This indicates that 17αE2 does reduce aspects of androgenic signaling, potentially explaining the resemblance of specific phenotypes to castrated males, and the lack of response in castrated males that already have low testosterone and DHT.

Although male mice treated with 17αE2 resemble castrated males in a set of skeletal muscle phenotypes, it is important to note that other aspects of sexual dimorphism normally controlled by gonadal hormones remain intact after 17αE2 treatment. Sex differences in the circulating concentrations of IGFl, leptin, and adiponectin persist with 17αE2 treatment (Garratt, Bower et al., 2017), in spite of the dependence of these sexual dimorphisms on gonadal hormones. The role of testicular and ovarian hormone release in control of sexual dimorphism is governed by sex steroids and their metabolites at various different levels, and at different developmental time points, and we speculate that adult-onset 17αE2 treatment may interfere with steroidogenic actions at specific sites while leaving others intact. For example, 17αE2 is capable of suppressing 5-alpha-reductase activity in vitro, the main enzyme that mediates conversion of testosterone to DHT (Schriefers, Wright, Rozman, & Hevert, 1991). This would be expected to dampen signaling through the androgen receptor, including reducing the weight of seminal vesicle glands, without major feedback effects on other aspects of the hypothalamic–pituitary–gonadal axis (HPG) (Mahendroo, Cala, Hess, & Russell, 2001). Alternatively, 17αE2 could alter HPG axis feedback through binding to estrogen receptors in specific brain areas, which in male mice is partly mediated by negative feedback of the HPG axis after aromatization of testosterone to 17β estradiol (Fisher, Graves, Parlow, & Simpson, 1998). At the dose provided in this study, 17αE2 is capable of activating classical estrogen receptors (ER) in mice, as evidenced by the uterotrophic effects observed in ovarietomized female mice (Strong et al., 2016). Such stimulation in regions like the hypothalamus and pituitary could elicit negative feedback for the HPG axis, suppressing LH and FSH release and subsequent gonadal hormone release, while maintaining ER activation in the brain. In female mice, 17αE2 reduced the abundance of amino acids in muscle, and this female-specific metabolomic effect was not seen in ovarietomized females, similar to ovarian hormone-dependent female-specific metabolomic responses in the liver (Garratt et al., 2018). This indicates that some female-specific responses to 17αE2 are also dependent on ovarian hormones and would be consistent with the idea that 17αE2 interferes with the HPG axis in both sexes, but that this interference has observable beneficial health effects only in males. We have also shown that treating male mice with 17αE2 leads to a major male-specific increase in hepatic estriol levels (Garratt et al., 2018), suggesting that 17αE2 may also be metabolized to additional estrogens in a sex-specific way. Understanding the causal role of individual aspects of steroid signaling in aging, in central and peripheral tissues, may provide a major insight into the role of specific components of the HPG axis in aging in both
sexes. This might ultimately lead to more precise pharmacological agents that provide the beneficial effects of sex-steroid signaling for aging, while minimizing or ablating their negative effects on other aspects of health.

4 | EXPERIMENTAL PROCEDURES

A detailed outline of all experimental procedures and statistical approaches is found in the supplementary information. UM-HET3 mice were produced and maintained as previously described (Miller et al., 2014; Strong et al., 2008). Mice were given free access to water and were fed Purina 5LG6 after weaning. Mice were group housed in ventilated cages and were transferred to fresh cages every 14 days. Temperature was maintained within the range of 21–23°C. At 3 months of age, all animals in cohort 1 went through castration, ovariectomy or a sham procedure as previously described (Garratt, Bower et al., 2017; Garratt et al., 2018). Cohort 2 did not go through surgeries and had normal gonadal hormone production.

4.1 | Diets: Cohorts 1&2

At 4 months of age, animals were randomly allocated to control or 17aE2 treatment. Animals in the control group remained on the 5LG6 diet, while animals allocated to 17aE2 had their diet switched to a food containing this drug at 14.4 ppm (see Strong et al. 2016). In cohort 2, a randomly selected subset of animals was maintained on the control diet until 16 months of age and then was switched to be treated with 17aE2 for the last 6 months of treatment.

4.2 | Rotarod and grip strength tests

Animals in cohort 1 were tested for their ability to balance on an accelerating rotarod at 24 months of age. Animals were placed on the rotarod and the trial began with the spindle revolving at 5 revolutions per minute (RPM) and increased to 40 RPM gradually over a 5-min period. The time at which the animal fell off the rotarod was used as a score, with each animal tested three times and the mean score used in analysis. The second cohort underwent the same testing protocol at 22 months of age. A subset of animals in cohort 2 were tested for grip strength using an EB1-BIO-GT3 grip strength meter with an EB1-GRIP-Mouse Grid. Subjects were removed from their cage by the base of the tail and suspended above the grid until their forepaws gripped the grid. The tail was gently pulled in a horizontal direction away from the grid until the mouse released its grip. The maximal force was recorded. Each animal was tested six times with a 10 s rest between each. The mean of the six tests was used for analysis. All tests were conducted by an experimenter blind to treatment group and surgery status.

4.3 | Euthanasia, tissue harvesting and processing

Animals were euthanized and tissues harvested during the morning after 18 hr of fasting. Tissues were weighed and then immediately frozen with liquid nitrogen and stored at −70°C unless otherwise stated. Deleted methodology for western blots, metabolomics, histology, and immunofluorescence is in the supplementary information.

ACKNOWLEDGMENTS

We thank Roxann Alonso, Amanda Keeble, Marcus Lehr, Natalie Perry, Sabrina Van Roekel, and Lynn Winkelman for technical assistance with mouse husbandry, surgery, and dissections. MG acknowledges support of a fellowship from the Michigan Society of Fellows. Work was supported by grants from the National Institutes of Health (AG023122, AG022303 & ES030158), The Paul F. Glenn Center for Biology of Aging Research, and The American Federation for Aging Research (Junior Faculty Grant).

CONFLICT OF INTEREST

None declared.

REFERENCES

Austad, S. N., & Fischer, K. E. (2016). Sex differences in lifespan. Cell Metabolism, 23(6), 1022–1033. https://doi.org/10.1016/j.cmet.2016.05.019

Bansal, A., Zhu, L. J., Yen, K., & Tissenbaum, H. A. (2015). Uncoupling lifespan and healthspan in Caenorhabditis elegans longevity mutants. PNAS, 112(3), E277–E286.

Basaria, S., Civello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., … Zhang, A. (2010). Adverse events associated with testosterone administration. New England Journal of Medicine, 363(2), 109–122. https://doi.org/10.1056/NEJMoa1000485

Chen, W. Y., & Colditz, G. A. (2007). Risk factors and hormone-receptor status: Epidemiology, risk-prediction models and treatment implications for breast cancer. Nature Clinical Practice Oncology, 4(7), 415–423. https://doi.org/10.1038/ncponc0851

Colby, S. L., & Ortmann, J. M. (2017). Projections of the size and composition of the US population: 2014 to 2060: Population estimates and projections.

Coquelin, A., & Desjardins, C. (1982). Luteinizing hormone and testosterone secretion in young and old male mice. American Journal of Physiology-Endocrinology and Metabolism, 243(3), E257–E263. https://doi.org/10.1152/ajpendo.1982.243.3.E257

Fisher, C. R., Graves, K. H., Parlow, A. F., & Simpson, E. R. (1998). Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proceedings of the National Academy of Sciences of the United States of America, 95(12), 6965–6970. https://doi.org/10.1073/pnas.95.12.6965

Garratt, M., Bower, B., Garcia, G. G., & Miller, R. A. (2017). Sex differences in lifespan extension with acarbose and 17α-estradiol: Gonadal hormones underlie male-specific improvements in glucose tolerance and mTORC2 signaling. Aging Cell, 16(6), 1256–1266. https://doi.org/10.1111/acel.12656

Garratt, M., Lagerborg, K. A., Tsai, Y. M., Galecki, A., Jain, M., & Miller, R. A. (2018). Male lifespan extension with 17α-estradiol is linked to a sex-specific metabolomic response modulated by gonadal hormones in mice. Aging Cell, 17, e12786. https://doi.org/10.1111/acel.12786

Garratt, M., Nakagawa, S. N., & Simons, M. J. (2018). Male lifespan extension with 17α-estradiol is linked to a sex-specific metabolomic response modulated by gonadal hormones in mice. Aging Cell, 17, e12786. https://doi.org/10.1111/acel.12489
Garratt, M., Nakagawa, S., & Simons, M. J. P. (2017). Life-span extension with reduced somatotropic signaling: Moderation of aging effect by signal type, sex, and experimental cohort. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*, 72(12), 1620–1626. https://doi.org/10.1093/gerona/glx010

Gonzalez-Freire, M., Diaz-Ruiz, A., & de Cabo, R. (2016). 17α-estradiol: A novel therapeutic intervention to target age-related chronic inflammation. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*, 72(1), 1–2.

Hansen, M., & Rubinsztein, D. C. (2018). Autophagy as a promoter of longevity: Insights from model organisms. *Nature Reviews Molecular Cell Biology*, 19(9), 579–593. https://doi.org/10.1038/s41580-018-0033-y

Hepple, R. T., Ross, K. D., & Remperther, A. B. (2004). Fiber atrophy and hypertrophy in skeletal muscles of late middle-aged Fischer 344 x Brown Norway F1 hybrid rats. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*, 59(2), 108–117. https://doi.org/10.1093/gerona/59.2.B108

Holzenberger, M., Dupont, J., Ducos, B., Leneuve, P., Geloen, A., Even, P. C., ... Le Bouc, Y. (2003). IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. *Nature*, 421(6919), 182–187. https://doi.org/10.1038/nature01298

Hustrom, A. M., Dillon, E. L., Urban, R. J., & Sheffield-Moore, M. (2012). The role of androgens and estrogens on healthy aging and longevity. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*, 67(11), 1140–1152. https://doi.org/10.1093/gerona/gso068

Jiao, Q., Puznak, A. M., Huber, D., Vary, T. C., & Lang, C. H. (2009). Catabolization differentially alters basal and leucine-stimulated tissue protein synthesis in skeletal muscle and adipose tissue. *American Journal of Physiology - Endocrinology and Metabolism*, 297(5), E1222–E1232. https://doi.org/10.1152/ajpendo.00473.2009

Kammoun, M., Cassar-Malek, I., Meunier, B., & Picard, B. (2014). A simplified immunochemical classification of skeletal muscle fibres in mouse. *European Journal of Histochemistry: EHJ*, 58(2), 2254.

Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., ... Baur, J. A. (2012). Rapamycin-mediated insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. *Experimental Gerontology*, 47(12), 913–918. https://doi.org/10.1016/j.exger.2012.07.013

Richardson, A., Fischer, K. E., Speakman, J. R., De Cabo, R., Mitchell, S. J., Peterson, C. A., ... Miller, R. A. (2015). Measures of healthspan as indices of aging in mice—a recommendation. *Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences*, 71(4), 427–430. https://doi.org/10.1093/gerona/glv080

Robine, J.-M., & Cubaynes, S. (2017). Worldwide demography of centenarians. *Mechanisms of Ageing and Development*, 165, 59–67. https://doi.org/10.1016/j.mad.2017.03.004

Rossetti, M. L., Steiner, J. L., & Gordon, B. S. (2017). Androgen-mediated regulation of skeletal muscle protein balance. *Molecular and Cellular Endocrinology*, 447, 35–44. https://doi.org/10.1016/j.mce.2017.02.031

Russ, D. W., Gregg-Cornell, K., Conaway, M. J., & Clark, B. C. (2012). Evolving concepts on the age-related changes in muscle quality*. *Journal of Cachexia, Sarcopenia and Muscle*, 3(2), 95–109. https://doi.org/10.1007/s13539-011-0054-2

Schriever, H., Wright, M. C., Rozman, T., & Hevert, F. (1991). Inhibition of testosterone metabolism by 17α-estradiol in rat liver slices. *Arzneimittel-Forschung*, 41(11), 1186–1189.

Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. L., ... Withers, D. J. (2009). Ribosomal protein S6 kinase 1 signaling regulates mammalian lifespan. *Science*, 326(5949), 140–144. https://doi.org/10.1126/science.1177221

Serra, C., Sandor, N. L., Jang, H., Lee, D., Toraldo, G., Guarneri, T., ... Bhasin, S. (2013). The effects of testosterone deprivation and supplementation on proteasomal and autophagy activity in the skeletal muscle of the male mouse: Differential effects on high-androgen responder and low-androgen responder muscle groups. *Endocrinology*, 154(12), 4594–4606. https://doi.org/10.1210/en.2013-1004

Stanworth, R. D., & Jones, T. H. (2008). Testosterone for the aging male: Current evidence and recommended practice. *Clinical Interventions in Aging*, 3(1), 25–44.

Steffen, K. K., & Dillen, A. (2016). A ribosomal perspective on proteostasis and aging. *Cell Metabolism*, 23(6), 1004–1012. https://doi.org/10.1016/j.cmet.2016.05.013

Steyn, F. J., Ngo, S. T., Chen, V. P., Bailey-Dowens, L. C., Xie, T. Y., Ghadamli, M., ... Stout, M. B. (2018). 17α-estradiol acts through hypothalamic pro-opiomelanocortin expressing neurons to reduce feeding behavior. *Aging Cell*, 17(1), https://doi.org/10.1111/acel.12338

Strong, R., Miller, R. A., Antebi, A., Astle, C. M., Bogue, M., Denzel, M. S., ... Harrison, D. E. (2016). Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. *Aging Cell*, 15(7), 935–946. https://doi.org/10.1111/acel.12513

Stout, M. B., Beyer, F. J., Jurczak, M. J., Camporeze, J.-P.-G., Zhu, Y., Hawse, J. R., ... Kirkland, J. L. (2016). 17α-estradiol alleviates age-related metabolic and inflammatory dysfunction in male mice without inducing feminization. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences*, 72(1), 3–15. https://doi.org/10.1093/gerona/glv039

Stron, R., Miller, R. A., Antebi, A., Astle, C. M., Bogue, M., Denzel, M. S., ... Harrison, D. E. (2018). Nondihydrogastricaric acid and aspirin increase lifespan of genetically heterogeneous male mice. *Aging Cell*, 17(5), 641–650. https://doi.org/10.1111/agec.12496

Strong, R., Miller, R. A., Astle, C. M., Floyd, R. A., Flurkey, K., Hensley, K. L., ... Harrison, D. E. (2008). Nondihydrogastricaric acid and aspirin increase lifespan of genetically heterogeneous male mice. *Aging Cell*, 7(5), 641–650. https://doi.org/10.1111/j.1474-9726.2008.00414.x

Tao, Z., Zheng, L. D., Smith, C., Luo, J., Robinson, A., Almeida, F. A., ... Cheng, Z. (2018). Estradiol signaling mediates gender difference in visceral adiposity via autophagy. *Cell Death & Disease*, 9(3), 309. https://doi.org/10.1038/s41419-018-0372-9

Tsai, S., Sitzmann, J. M., Dastidar, S. G., Rodriguez, A. A., Vu, S. L., McDonald, C. E., ... Kennedy, B. K. (2015). Muscle-specific 4E-BP1
signaling activation improves metabolic parameters during aging and obesity. *The Journal of Clinical Investigation*, 125(8), 2952–2964. https://doi.org/10.1172/JCI77361

Williams, G. N., Higgins, M. J., & Lewek, M. D. (2002). Aging skeletal muscle: Physiologic changes and the effects of training. *Physical Therapy*, 82(1), 62–68. https://doi.org/10.1093/ptj/82.1.62

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.